Work

First-in-human phase I “basket” study of Debio1347 (CH5183284), a novel FGFR inhibitor, in patients with FGFR genomically activated advanced solid tumors.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.tps2629

Authors: Martin Henner Voss, Barbara Adamo, Rebecca Suk Heist, Leena Gandhi, Corinne Moulon, Hiroaki Tanaka, Nobuya Ishii, Anne Vaslin, Yuko Aoki, Valerie Nicolas-Metral, Silvano Brienza, Claudio Zanna, Keith Flaherty, Josep Tabernero, Jose Baselga

Institutions: Memorial Sloan Kettering Cancer Center, Vall d'Hebron Hospital Universitari, Massachusetts General Hospital, Dana-Farber Cancer Institute, Debiopharm (Switzerland), Chugai Pharmaceutical Co., Ltd. (Japan)

Language: English

Topic: Fibroblast Growth Factor Research

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2603005017

Cites:

Cited by: 2

Related to: 10